Paradigm Biopharmaceuticals Ltd has released a press release.
Paradigm delivers IND to US FDA for Pivotal OA Program
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Story so far
Earlier from Paradigm Biopharmaceuticals
- Consistent pain reduction and improvement in function data
- Response to ASX Query
- R&D Investor Presentation
- Paradigm receives postive feedback from FDA type c meeting
- Paradigm Provides Phase 3 Clinical Trial Update
Later from Paradigm Biopharmaceuticals
- Paradigm and Bene Execute New Collaboration Agreement
- Paradigm doses first participant in Synovial Fluid Trial
- Paradigm provides ind application update
- Paradigm achieves first revenue
- Ind questions received from US FDA
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals